Company intelligence / Profile preview

Kadence Bio

London, England, United Kingdomkadencebio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Kadence Bio completed Phase 1 safety studies for its lead asset KH-001 in Q3 2024, demonstrating safety and an advantageous pharmacokinetic profile for on-demand dosing. The company is planning to initiate Phase 2 trials in 2025.

Therapeutic areas: PsychiatryMen's Health
Modalities: Small moleculesAlkaloid compounds
Industry: Biotech

Drug pipeline

1 asset

KH-001

Beyond the preview

Go deeper on Kadence Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kadence Bio.

Explore the full profile